Tumour endothelial cells acquire drug resistance in a tumour microenvironment
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Tumour growth is dependent on angiogenesis, and tumour blood vessels are recognized as an important target for cancer therapy. Tumour endothelial cells (TECs) are the main targets of anti-angiogenic therapy. Unlike the traditionally held view, some TECs may be genetically abnormal and might acquire drug resistance. Therefore, we investigated the drug resistance of TECs and the mechanism by which it is acquired. TECs show resistance to paclitaxel through greater mRNA expression of multidrug resistance 1, which encodes P-glycoprotein, as compared with normal endothelial cells. We found that high levels of vascular endothelial growth factor in tumour-conditioned medium may be responsible for upregulated P-glycoprotein expression. This is a novel mechanism for the acquisition of drug resistance by TECs in a tumour microenvironment. This review focuses on the possibility that TECs can acquire drug resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Anti-VEGF therapies normalize the vasculature (69), which helps to provide efficient drug delivery, besides its anti-angiogenic effects.”
BackgroundCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 2×
“I Resistance in tumour cells Compensatory upregulation of several pro-angiogenic growth factors Casanovas et al. (18) Eikesdal and Kalluri (23) Vascular co-option Rubenstein et al. (24) Döme et al. (25) Leenders et al. (26) Transdifferentiation of tumour cells Ricci-Vitiani et al. (27) Wang et al. (28) Soda et al. (2…”
BackgroundVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Research works printed but not linked: 2
- 2004, Clinical Cancer Research, 15, 6222
- Grange, 2006, Oncology reports, 15, 381
Cited by
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Eelen, G., de Zeeuw, P., Treps, L., Harjes, U., Wong, B. W., & Carmeliet, P. (2018) · Physiological Reviews · doi:10.1152/physrev.00001.2017 · Cited by 572
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Kareva, I., Waxman, D. J., & Lakka Klement, G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.039 · Cited by 249
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
3D tumor models: History, advances and future perspectives
Benien, P., & Swami, A. (2014) · Future Oncology · doi:10.2217/fon.13.274 · Cited by 208
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Nadali Hezaveh, M., Khosravi, S., Kamali Andani, M., Cordani, M., Basiri, M., & Ghavami, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176013 · Cited by 184
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
Simsek, C., Esin, E., & Yalcin, S. (2019) · Journal of Oncology · doi:10.1155/2019/5483791 · Cited by 141
Kondoh, M., Ohga, N., Akiyama, K., Hida, Y., Maishi, N., Towfik, A. M., Inoue, N., Shindoh, M., & Hida, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080349 · Cited by 109
Self-citationCao, Z., Shang, B., Zhang, G., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.08.001 · Cited by 109
Multiple biological functions and pharmacological effects of lycorine
Cao, Z., Yang, P., & Zhou, Q. (2013) · Science China Chemistry · doi:10.1007/s11426-013-4967-9 · Cited by 108
Phyto-polyphenols as potential inhibitors of breast cancer metastasis
Avtanski, D. B., & Poretsky, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0032-7 · Cited by 105
Sun, H., Zhu, A., Zhou, X., & Wang, F. (2017) · Oncotarget · doi:10.18632/oncotarget.16991 · Cited by 75
Brandes, A. A., Gil‐Gil, M., Saran, F. H., Carpentier, A. F., Nowak, A. K., Mason, W. P., Zagonel, V., Dubois, F., Finocchiaro, G., Fountzilas, G., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0290 · Cited by 70
A bladder cancer microenvironment simulation system based on a microfluidic co-culture model
Liu, P.-F., Cao, Y.-W., Zhang, S.-D., Zhao, Y., Liu, X.-G., Shi, H.-Q., Hu, K.-Y., Zhu, G.-Q., Ma, B., & Niu, H.-T. (2015) · Oncotarget · doi:10.18632/oncotarget.6070 · Cited by 68
Dong, Y., Pan, Q., Li, J., Chen, Z., Zhang, F.-F., Liu, Y., Xing, H., Shi, M., Li, J., Li, X., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.076 · Cited by 64
MicroRNA-induced drug resistance in gastric cancer
Dehghanzadeh, R., Jadidi‐Niaragh, F., Gharibi, T., & Yousefi, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.009 · Cited by 59
Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy
Huang, L., Perrault, C., Coelho-Martins, J., Hu, C., Dulong, C., Varna, M., Liu, J., Jin, J., Soria, C., Cazin, L., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-49 · Cited by 58
Chatterjee, S., Sinha, S., Molla, S., Hembram, K. C., & Kundu, C. N. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109902 · Cited by 55
Axl signaling is an important mediator of tumor angiogenesis
Tanaka, M., & Siemann, D. W. (2019) · Oncotarget · doi:10.18632/oncotarget.26882 · Cited by 51
Tocilizumab inhibits IL‐8 and the proangiogenic potential of triple negative breast cancer cells
Alraouji, N. N., & Aboussekhra, A. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23270 · Cited by 49
Stromal cells in breast cancer as a potential therapeutic target
Dykes, S. S., Hughes, V. S., Wiggins, J. M., Fasanya, H. O., Tanaka, M., & Siemann, D. W. (2018) · Oncotarget · doi:10.18632/oncotarget.25245 · Cited by 49
Ciesielski, O., Biesiekierska, M., Panthu, B., Vialichka, V., Pirola, L., & Balcerczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072606 · Cited by 48
MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics
Alsidawi, S., Malek, E., & Driscoll, J. J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610508 · Cited by 48
Tumor endothelial cells as a potential target of metronomic chemotherapy
Kim, J. Y., & Kim, Y. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-018-01102-z · Cited by 47
Li, M., Xing, S., ZHANG, H., Shang, S., Li, X., REN, B., Gaiyun, L., CHANG, X., Li, Y., & Li, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4547 · Cited by 45
Resistance to metronomic chemotherapy and ways to overcome it
Martínez, M. C. R., Parra, K., Saluja, R., Francia, G., & Emmenegger, U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.027 · Cited by 41
Necrosis in the Tumor Microenvironment and Its Role in Cancer Recurrence
Karsch-Bluman, A., & Benny, O. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35727-6_6 · Cited by 37
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy
Landreneau, J. P., Shurin, M. R., Agassandian, M., Keskinov, A. A., Ma, Y., & Shurin, G. V. (2013) · Cancer Microenvironment · doi:10.1007/s12307-013-0141-3 · Cited by 37
JAK2 regulates paclitaxel resistance in triple negative breast cancers
Han, J., Yun, J., Quan, M., Kang, W., Jung, J. G., Heo, W., Li, S., Lee, K. J., Son, H., Kim, J. H., et al. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02138-3 · Cited by 35
Bani, M. R., Decio, A., Giavazzi, R., & Ghilardi, C. (2017) · Angiogenesis · doi:10.1007/s10456-017-9549-6 · Cited by 32
Yang, J., Ye, H., Fan, X., Li, Y., Wu, X., Zhao, M., Hu, Q., Ye, Y., Wu, L., Li, Z., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03666-3 · Cited by 31
Radandish, M., Mashhadi, N., Aghayan, A. H., Taghizadeh, M., Salehianfard, S., Yahyazadeh, S., Vakili, O., & Igder, S. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00695-8 · Cited by 30
Kaffas, A. E., Nofiele, J. T., Giles, A., Cho, S., Liu, S. K., & Czarnota, G. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093888 · Cited by 30
Bioprinting and its Use in Tumor-On-A-Chip Technology for Cancer Drug Screening: A Review
Fang, L., Liu, Y., Qiu, J., & Wan, W. (2022) · International Journal of Bioprinting · doi:10.18063/ijb.v8i4.603 · Cited by 28
Mabrouk, H. B., Zouari-Kessentini, R., Montassar, F., Koubaa, Z. A., Messadi, E., Guillonneau, X., Ayeb, M. E., Srairi‐Abid, N., Luis, J., Micheau, O., et al. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.02.008 · Cited by 28
Lu, R., Chiu, C., Liu, I.-J., Chang, Y., Liu, Y., & Wu, H. (2019) · Cancer Science · doi:10.1111/cas.14208 · Cited by 27
Recapitulating Tumorigenesis in vitro: Opportunities and Challenges of 3D Bioprinting
Kronemberger, G. S., Miranda, G. A. S. C., Tavares, R. S. N., Montenegro, B. M., Kopke, Ú. D. A., & Baptista, L. S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.682498 · Cited by 27
Metronomic Chemotherapy for Metastatic Breast Cancer
Krajnak, S., Battista, M. J., Hasenburg, A., & Schmidt, M. (2021) · Oncology Research and Treatment · doi:10.1159/000520236 · Cited by 22
Zhou, S. M., Ou, H., Wu, Y., Qi, D., Pei, X., Yu, X., Hu, X., & Wu, E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108434 · Cited by 22
Lu, H., Vannier, J., Huang, L., Hu, C., Liu, J., Wang, L., Jin, J., Janin, A., Li, H., Benedetto, M. D., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s67251 · Cited by 21
Zhuo, H., Lyu, Z., Su, J., He, J., Pei, Y., Cheng, X. J., Zhou, N., Lü, X., Zhou, S., & Zhao, Y. (2014) · Journal of Proteome Research · doi:10.1021/pr5006229 · Cited by 21
Vitale, D. L., Spinelli, F. M., Dago, D. D., Icardi, A., Demarchi, G., Caon, I., García, M. G., Bolontrade, M. F., Passi, A. G., Cristina, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26379 · Cited by 21
Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier
Pascual‐Pasto, G., Olaciregui, N. G., Opezzo, J. A. W., Castillo‐Ecija, H., Cuadrado‐Vilanova, M., Paco, S., Rivero, E. M., Vilà-Ubach, M., Restrepo‐Perdomo, C. A., Torrebadell, M., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.018 · Cited by 21
Bourn, M. D., Mohajerani, S. Z., Mavria, G., Ingram, N., Coletta, P. L., Evans, S. D., & Peyman, S. A. (2023) · Lab on a Chip · doi:10.1039/d2lc00963c · Cited by 20
Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells
Norton, K., Pandey, N. B., Han, Z., & Popel, A. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s65055 · Cited by 20
Meng, M., Liao, H., Zhang, B., Pan, Y., Kong, Y., Liu, W., Yang, P., Huo, Z., Cao, Z., & Zhou, Q. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.12.006 · Cited by 19
Organotypic Modeling of the Tumor Landscape
Haykal, M. M., Nahmias, C., Varon, C., & Martin, O. C. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606039 · Cited by 19
Mohr, T. T., Katz, S., Paulitschke, V., Aizarani, N., & Tolios, A. (2021) · Cancers · doi:10.3390/cancers13081768 · Cited by 18
Tamura, K., Yoshie, M., Miyajima, E., Kano, M., & Tachikawa, E. (2013) · ISRN Pharmacology · doi:10.1155/2013/279593 · Cited by 17
Reconstitution of human tissue barrier function for precision and personalized medicine
Kim, J., Yoon, T., Lee, S. W., Kim, P. J., & Kim, Y. (2024) · Lab on a Chip · doi:10.1039/d4lc00104d · Cited by 16
Kim, C., Suh, J., Heo, C., Lee, C. K., Shim, W. H., Park, B. W., Cho, G., Lee, D., Woo, D., Kim, S., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1624 · Cited by 15
Endothelial‐specific CXCL12 regulates neovascularization during tissue repair and tumor progression
Hostler, A. C., Hahn, W. W., Hu, M. S.-M., Rennert, R. C., Fischer, K. S., Barrera, J. A., Duscher, D., Januszyk, M., Henn, D., Sivaraj, D., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401307r · Cited by 13
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells
Huang, L., Hu, C., Benedetto, M. D., Varin, R., Liu, J., Jin, J. J., Wang, L., Vannier, J., Janin, A., Lu, H., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2819 · Cited by 10
Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation
Swetha, K. L., Maravajjala, K. S., Li, S., Singh, M. S., & Roy, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01194-7 · Cited by 9
Modulation of the interplay between p53, ICAM-1 and VEGF in drug-treated LoVo colon cancer cells
Hotnog, C. M., Mihaila, M. A., Puiu, L., BOTEZATU, A., Roman, V., Popescu, I., Bostan, M., & Braşoveanu, L. I. (2019) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/24.2/261.270 · Cited by 9
Drug resistance-related miRNAs in hepatocellular cancer
Hong, L., Han, Y., Zhang, H., Zhao, Q., Wu, K., & Fan, D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.881713 · Cited by 8
Endothelial CXCL12 regulates neovascularization during tissue repair and tumor progressionPreprint
Maan, Z. N., Hu, M. S.-M., Rennert, R. C., Barrera, J. A., Duscher, D., Januszyk, M., Henn, D., Chen, K., Sivaraj, D., Whittam, A. J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3809993 · Cited by 6
La résistance aux traitements antiangiogéniques: Une actualité clinique et scientifique
Gu, Y., Lu, H., Boisson‐Vidal, C., Li, H., Bousquet, G., Janin, A., & Benedetto, M. D. (2016) · médecine/sciences · doi:10.1051/medsci/20163204015 · Cited by 5
The Role of Stromal Proteolytic Systems in Cancer Progression (Review)
Kugaevskaya, E. V., Timoshenko, O. S., Gureeva, T. A., & Solovieva, N. I. (2019) · General Reanimatology · doi:10.15360/1813-9779-2019-5-106-126 · Cited by 2
Kuang, X., Ren, Y. L., Chen, C., Su, J., Li, H., Liu, S., Sun, T., Mu, D.-Y., Lu, J. N., Chen, L., et al. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147082 · Cited by 2
Activated melanoma vessels: A sticky point for successful immunotherapy
Weishaupt, C., Goerge, T., & Loser, K. (2020) · Experimental Dermatology · doi:10.1111/exd.14203 · Cited by 2
Arrivi, G., Spada, F., Frassoni, S., Bagnardi, V., Laffi, A., Rubino, M., Gervaso, L., & Fazio, N. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13189 · Cited by 2
Surviving Stress with the Tumour Microenvironment: Understanding Complex Cell - Cell Interactions
Dawson, R. (2021) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.15102033 · Cited by 2
Delivery of SN-38 in pediatric solid tumors
Martínez, C. M. (2016) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Bani, M. R., Decio, A., Giavazzi, R., & Ghilardi, C. (2017) · Angiogenesis · doi:10.1007/s10456-017-9558-5 · Cited by 1
ECM internalisation as a novel modulator of cancer cell growth/survival
Nazemi, M. (2021) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Towards Personalized Cancer Therapy: Microfluidic Approaches for Drug Screening
Chang, C.-T. (2014) · ResearchWorks at the University of Washington (University of Washington)
Tandia, M. (2017) · theses.fr (ABES) · doi:10.70675/330e33dfzfaa5z42fbz898dz9d67399c02e9
Parra, K., Vidal, C., Valenzuela, P., Jallad, S., Rodriguez, G., Felder, M. S., Lerma, N., Bocci, G., Emmenegger, U., Kirken, R. A., et al. (2014) · scholarworks - UTEP (The University of Texas at El Paso)
Morbidelli, L., & Donnini, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00018-4
miR-603 mediates thyroid cancer progression by inhibiting HACE1-Dependent YAP1 degradation
Li, T., Chu, J., Guangjun, Z., & Jiang, G. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110453
Metronomische Chemotherapie bei metastasiertem Mammakarzinom
Krajnak, S. (2024) · Gutenberg Open Science · doi:10.25358/openscience-10535
Targeting the cell cycle : A novel therapeutic strategy against ATIP3- deficient breast cancer
Haykal, M. M. (2023) · theses.fr (ABES) · doi:10.70675/03dee32bz395cz469ez9a0dzf4c5f2e84330
Metadata
- Authors
- Hida, K., Akiyama, K., Ohga, N., Maishi, N., & Hida, Y.
- Affiliations
- Hokkaido University (JP)
- Corresponding author
- Hida, K.
- Venue
- Journal of Biochemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-03
- Volume
- 153
- Issue
- 3
- Pages
- 243-249
- ISSN
- 0021-924X (ISSN-L)
- OpenAlex
- W2151576046
- Semantic Scholar
- 4c3a45115bfa8bfe60eb8df9b13a676b29cfa83a
- Cited by
- 68
- References
- 70
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 5 · 2016: 4 · 2015: 2 · 2014: 10 · 2013: 6
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (21659458, 23390457, 24791958, 24890007, 23890009)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor endothelial cells, drug resistance, multidrug resistance 1, P-glycoprotein, paclitaxel, vascular endothelial growth factor, tumor microenvironment, anti-angiogenic therapy, tumor angiogenesis
- MeSH terms
- Humans, Models, Genetic, Neoplasms, Neovascularization, Pathologic, Gene Expression Regulation, Neoplastic, ATP Binding Cassette Transporter, Subfamily B, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Vascular Endothelial Growth Factor A, Endothelial Cells, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.